Cancer screening, honestly — real benefit, real trade-offs

Screening can catch cancer early and save lives — and it isn’t free of harm. The honest headline: the best-studied screens (like bowel and breast) genuinely reduce cancer death, but with real trade-offs like overdiagnosis, so the sensible message is informed screening, not blind faith or blanket refusal.

Why screening is genuinely valuable — and not simple

Screening looks for cancer (or its precursors) before symptoms appear, when treatment works better. For several cancers that clearly saves lives. But screening healthy people also carries costs: false alarms, invasive follow-ups, and overdiagnosis — finding cancers that would never have caused harm but still get treated.

Honest screening means understanding both sides, not just the reassuring half.

What the evidence shows

Real benefit, honestly quantified.

• Bowel screening cuts colorectal cancer — In a large trial, an invitation to a single screening colonoscopy reduced 10-year colorectal-cancer risk — and among those who actually got scoped, the estimated reduction in cancer (and death) was substantially larger. Uptake matters: the benefit is bigger if you actually attend. (established)
• Mammography reduces breast-cancer death — with overdiagnosis — An independent expert review estimated screening cuts breast-cancer mortality by about 20% in invited women, while also overdiagnosing some cancers that would never have caused harm. Both the benefit and the harm are real; it’s a genuine trade-off, not a scam. (established)

How to think about it

• Follow evidence-based programmes for your age/risk — National screening programmes (bowel, breast, cervical, and lung for heavy smokers) are designed around where benefit outweighs harm. Higher personal or family risk can change the timing — discuss it with your clinician. (note)
• Beware unproven “full-body” scans and blood tests — Marketed whole-body MRIs and many multi-cancer blood tests are not proven to save lives and can generate false alarms, anxiety and cascades of testing. Proven programmes first; treat the rest with caution. (hype)

What we still don’t know

• How to avoid overdiagnosis We can’t yet reliably tell which screen-detected cancers would have stayed harmless, so some people are treated unnecessarily.
• The value of newer multi-cancer tests Blood-based multi-cancer early-detection tests are promising but not yet proven to reduce deaths — trials are ongoing.

Key terms

• Screening Testing people without symptoms to catch disease (or its precursors) early.
• Overdiagnosis Finding a cancer that would never have caused harm in someone’s lifetime, leading to unnecessary treatment.
• Colonoscopy A camera examination of the bowel that can find and remove precancerous polyps.
• Mammography An X-ray screening test for breast cancer.
• False positive A test result suggesting cancer when there is none, leading to further tests and anxiety.